168 related articles for article (PubMed ID: 38412903)
21. Pathological review of cardiac amyloidosis using autopsy cases in a single Japanese institution.
Tateishi Y; Yamada Y; Katsuki M; Nagata T; Yamamoto H; Kohashi K; Koga Y; Hashisako M; Kiyozawa D; Mori T; Kuboyama Y; Kakinokizono A; Miyazaki Y; Yamaguchi A; Tsutsui H; Ninomiya T; Naiki H; Oda Y
Pathol Res Pract; 2021 Nov; 227():153635. PubMed ID: 34653913
[TBL] [Abstract][Full Text] [Related]
22. Clinical and pathological studies of cardiac amyloidosis in transthyretin type familial amyloid polyneuropathy.
Hattori T; Takei Y; Koyama J; Nakazato M; Ikeda S
Amyloid; 2003 Dec; 10(4):229-39. PubMed ID: 14986482
[TBL] [Abstract][Full Text] [Related]
23. Sudden cardiac death and sarcoidosis of the heart in a young patient.
Jotterand M; Grabherr S; Lobrinus JA; Michaud K
Cardiovasc Pathol; 2017; 28():18-20. PubMed ID: 28282543
[TBL] [Abstract][Full Text] [Related]
24. Clinical profile and outcome of cardiac amyloidosis in a Spanish referral center.
López-Sainz Á; Hernandez-Hernandez A; Gonzalez-Lopez E; Domínguez F; Restrepo-Cordoba MA; Cobo-Marcos M; Gómez-Bueno M; Hernandez-Perez FJ; Oteo JF; Mirelis JG; Cavero MA; Moñivas V; Mingo Santos S; de Haro-Del Moral FJ; Krsnik I; Salas C; Bornstein B; Briceño A; López JA; Vázquez J; Alonso-Pulpón L; Segovia J; Garcia-Pavia P
Rev Esp Cardiol (Engl Ed); 2021 Feb; 74(2):149-158. PubMed ID: 32317158
[TBL] [Abstract][Full Text] [Related]
25. Tafamidis: a selective transthyretin stabilizer to treat wild-type ATTR amyloidosis and hereditary ATTR amyloidosis with cardiomyopathy.
Paton DM
Drugs Today (Barc); 2019 Dec; 55(12):727-734. PubMed ID: 31942875
[TBL] [Abstract][Full Text] [Related]
26. Amyloid myopathy: expanding the clinical spectrum of transthyretin amyloidosis-case report and literature review.
Ungericht M; Wanschitz J; Kroiss AS; Röcken C; Schuetz T; Messner M; Zaruba MM; Loescher WN; Poelzl G
J Nucl Cardiol; 2023 Aug; 30(4):1420-1426. PubMed ID: 35581484
[TBL] [Abstract][Full Text] [Related]
27. Design and Rationale the SCAN-MP (Screening for Cardiac Amyloidosis With Nuclear Imaging in Minority Populations) Study.
Ruberg FL; Blaner WS; Chiuzan C; Connors LH; Einstein AJ; Fine D; Helmke S; Kurian D; Pandey S; Raiszadeh F; Rodriguez C; Sabogal N; Teruya S; Winburn M; Chung WK; Cohn E; Miller EJ; Kelly JW; Maurer MS
J Am Heart Assoc; 2023 Apr; 12(8):e028534. PubMed ID: 37066788
[TBL] [Abstract][Full Text] [Related]
28. Frequency of hereditary transthyretin amyloidosis among elderly patients with transthyretin cardiomyopathy.
Maestro-Benedicto A; Vela P; de Frutos F; Mora N; Pomares A; Gonzalez-Vioque E; Briceño A; Cabrera E; Cobo-Marcos M; Dominguez F; Gonzalez-Lopez E; Segovia J; Lara-Pezzi E; Garcia-Pavia P
Eur J Heart Fail; 2022 Dec; 24(12):2367-2373. PubMed ID: 35999650
[TBL] [Abstract][Full Text] [Related]
29. Differential Myocyte Responses in Patients with Cardiac Transthyretin Amyloidosis and Light-Chain Amyloidosis: A Cardiac MR Imaging Study.
Fontana M; Banypersad SM; Treibel TA; Abdel-Gadir A; Maestrini V; Lane T; Gilbertson JA; Hutt DF; Lachmann HJ; Whelan CJ; Wechalekar AD; Herrey AS; Gillmore JD; Hawkins PN; Moon JC
Radiology; 2015 Nov; 277(2):388-97. PubMed ID: 25997029
[TBL] [Abstract][Full Text] [Related]
30. Genotype and Phenotype of Transthyretin Cardiac Amyloidosis: THAOS (Transthyretin Amyloid Outcome Survey).
Maurer MS; Hanna M; Grogan M; Dispenzieri A; Witteles R; Drachman B; Judge DP; Lenihan DJ; Gottlieb SS; Shah SJ; Steidley DE; Ventura H; Murali S; Silver MA; Jacoby D; Fedson S; Hummel SL; Kristen AV; Damy T; Planté-Bordeneuve V; Coelho T; Mundayat R; Suhr OB; Waddington Cruz M; Rapezzi C;
J Am Coll Cardiol; 2016 Jul; 68(2):161-72. PubMed ID: 27386769
[TBL] [Abstract][Full Text] [Related]
31. Nonbiopsy Diagnosis of Cardiac Transthyretin Amyloidosis.
Gillmore JD; Maurer MS; Falk RH; Merlini G; Damy T; Dispenzieri A; Wechalekar AD; Berk JL; Quarta CC; Grogan M; Lachmann HJ; Bokhari S; Castano A; Dorbala S; Johnson GB; Glaudemans AW; Rezk T; Fontana M; Palladini G; Milani P; Guidalotti PL; Flatman K; Lane T; Vonberg FW; Whelan CJ; Moon JC; Ruberg FL; Miller EJ; Hutt DF; Hazenberg BP; Rapezzi C; Hawkins PN
Circulation; 2016 Jun; 133(24):2404-12. PubMed ID: 27143678
[TBL] [Abstract][Full Text] [Related]
32. Optimal Echocardiographic Parameters to Improve the Diagnostic Yield of Tc-99m-Bone Avid Tracer Cardiac Scintigraphy for Transthyretin Cardiac Amyloidosis.
Cuddy SA; Datar Y; Ovsak G; Saith S; Murphy SP; Bay CP; Haddad M; Lilleness B; Muralidhar V; Pipilas A; Vuong J; Guardino E; Maurer MS; Ruberg FL; Falk RH; Dorbala S
Circ Cardiovasc Imaging; 2022 Nov; 15(11):e014645. PubMed ID: 36378779
[TBL] [Abstract][Full Text] [Related]
33. Transthyretin-related amyloidoses and the heart: a clinical overview.
Rapezzi C; Quarta CC; Riva L; Longhi S; Gallelli I; Lorenzini M; Ciliberti P; Biagini E; Salvi F; Branzi A
Nat Rev Cardiol; 2010 Jul; 7(7):398-408. PubMed ID: 20479782
[TBL] [Abstract][Full Text] [Related]
34. Transthyretin cardiac amyloidosis: an update on diagnosis and treatment.
Yamamoto H; Yokochi T
ESC Heart Fail; 2019 Dec; 6(6):1128-1139. PubMed ID: 31553132
[TBL] [Abstract][Full Text] [Related]
35. Noninvasive risk stratification of patients with transthyretin amyloidosis.
Kristen AV; Scherer K; Buss S; aus dem Siepen F; Haufe S; Bauer R; Hinderhofer K; Giannitsis E; Hardt S; Haberkorn U; Katus HA; Steen H
JACC Cardiovasc Imaging; 2014 May; 7(5):502-10. PubMed ID: 24726252
[TBL] [Abstract][Full Text] [Related]
36. Distinctive Patterns of Transthyretin Amyloid in Salivary Tissue: A Clinicopathologic Study of 92 Patients With Amyloid-containing Minor Salivary Gland Biopsies.
Jamet MP; Gnemmi V; Hachulla É; Dhaenens CM; Bouchindhomme B; Delattre C; Glowacki F; Hatron PY; Lacour A; Lamblin N; Launay D; Leleu X; Guiochon-Mantel A; Valleix S; Maurage CA; Copin MC; Buob D
Am J Surg Pathol; 2015 Aug; 39(8):1035-44. PubMed ID: 25828388
[TBL] [Abstract][Full Text] [Related]
37. Tafamidis: A First-in-Class Transthyretin Stabilizer for Transthyretin Amyloid Cardiomyopathy.
Park J; Egolum U; Parker S; Andrews E; Ombengi D; Ling H
Ann Pharmacother; 2020 May; 54(5):470-477. PubMed ID: 31735059
[No Abstract] [Full Text] [Related]
38. Causes of Cardiovascular Hospitalization and Death in Patients With Transthyretin Amyloid Cardiomyopathy (from the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial [ATTR-ACT]).
Miller AB; Januzzi JL; O'Neill BJ; Gundapaneni B; Patterson TA; Sultan MB; López-Sendón J
Am J Cardiol; 2021 Jun; 148():146-150. PubMed ID: 33667442
[TBL] [Abstract][Full Text] [Related]
39. [Neurological manifestations of ATTR amyloidosis].
Pernice HF; Hahn K
Inn Med (Heidelb); 2023 Sep; 64(9):848-854. PubMed ID: 37555967
[TBL] [Abstract][Full Text] [Related]
40. Update on Disease-Specific Biomarkers in Transthyretin Cardiac Amyloidosis.
Hood CJ; Hendren NS; Pedretti R; Roth LR; Saelices L; Grodin JL
Curr Heart Fail Rep; 2022 Oct; 19(5):356-363. PubMed ID: 35930129
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
